Rapid and robust B-cell depletion reported in preliminary phase II study of ublituximab
Relapsing remitting multiple sclerosis (RRMS) patients treated with ublituximab (TG-1101) have exhibited a median B-cell depletion of 99% at week four of an ongoing five month study, conducted by TG Therapeutics, Inc...Read more - http://www.ms-uk.org/rapid-and-robust-b ... mab-290617
Results of preliminary phase II study of ublituximab in RRMS
Results of preliminary phase II study of ublituximab in RRMS
MS-UK - http://www.ms-uk.org/
Re: Results of preliminary phase II study of ublituximab in
Thanks again. The news page of MS-UK is currently the best source of information in the web.
Re: Results of preliminary phase II study of ublituximab in
Thank you for this feedback, means a lot
MS-UK - http://www.ms-uk.org/
-
- Similar Topics
- Replies
- Views
- Last post
-
- 0 Replies
- 1622 Views
-
Last post by NHE
-
- 0 Replies
- 680 Views
-
Last post by DIM
-
- 0 Replies
- 2363 Views
-
Last post by NHE
-
- 0 Replies
- 1227 Views
-
Last post by frodo
-
- 2 Replies
- 4137 Views
-
Last post by DIM
-
- 1 Replies
- 2921 Views
-
Last post by Tif
-
- 0 Replies
- 2319 Views
-
Last post by NHE
-
- 1 Replies
- 1207 Views
-
Last post by Scott1
-
- 1 Replies
- 1851 Views
-
Last post by frodo